Capture of CH1-Containing Bispecific AntibodiesEvaluating an Alternative to Protein A

摘要

Bispecific antibodies (BsAbs) are designed to recognize and bind two different antigens, in many cases for the purpose of immune effector-cell activation to destroy cancer cells (l). Such BsAbs mediate cell killing by binding simultaneously to an antigen that is overexpressed on tumor cells and to the CD3 receptor, activating cytotoxic T lymphocytes (2). Using proprietary UniRat human heavy-chain technology combined with OmniFlic human fixed-light-chain antibody technology licensed from Ligand Pharmaceuticals, Teneobio has produced several BsAbs, each targeting a different tumor antigen and CD3 (3).